AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
aTyr Pharma completes last patient visit in Phase 3 EFZO-FIT study.
ByAinvest
Thursday, Aug 7, 2025 4:08 pm ET1min read
• aTyr Pharma completes last patient visit in Phase 3 EFZO-FIT study. • Topline results expected in mid-September 2025. • Efzofitimod is for pulmonary sarcoidosis treatment. • aTyr Pharma is a clinical stage biotechnology company.
San Diego, CA — aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company, has completed the last patient visit in its Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. The company expects to report topline results in mid-September 2025 [1].The EFZO-FIT™ study is a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of efzofitimod in patients with pulmonary sarcoidosis. The study enrolled 268 patients across 85 centers in nine countries and is designed to assess the absolute change in steroid use from baseline to week 48 as the primary endpoint [1].
aTyr Pharma anticipates that the completion of this study represents a significant milestone in its clinical program for efzofitimod in interstitial lung disease (ILD). The company is also advancing efzofitimod in the Phase 2 EFZO-CONNECT™ study for systemic sclerosis (SSc)-related ILD and has advanced ATYR0101 to the investigational new drug (IND) candidate stage for pulmonary fibrosis [1].
The company's financial position remains strong, with cash and investment position at $83.2 million as of June 30, 2025, and an additional $30.7 million raised through an at-the-market (ATM) offering with Jefferies LLC [1]. The company expects its cash runway to be sufficient to fund its operations for a period of one year following the Phase 3 EFZO-FIT™ readout.
aTyr Pharma is focused on leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Efzofitimod is a first-in-class biologic immunomodulator in clinical development for the treatment of ILD, a group of immune-mediated disorders that can cause inflammation and fibrosis of the lungs [1].
References:
[1] https://www.nasdaq.com/press-release/atyr-pharma-announces-second-quarter-2025-results-and-provides-corporate-update-2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet